71 results about "ZINC FINGER ANTIVIRAL PROTEIN" patented technology

The invention provides an expression vector containing a recombined blue algae antiviral protein N nucleotide sequence, a host cell containing the expression vector and a method for preparing recombined blue algae antiviral protein on the basis to obtain the recombined blue algae antiviral protein and further proves that the expression vector and/or the host cell and/or the recombined blue algae antiviral protein can be applied to prepare an antiviral medicament. The method of the invention overcomes the disadvantages of low yield, an easily formed inclusion body and difficult purification and the like in the prior art. Peptide mass fingerprinting of the recombined CVN protein prepared by the method is totally consistent with theoretical peptide mass fingerprinting; and an antiviral experiment proves that the recombined protein has good antiviral activity.

The invention relates to anti-viral protein. The anti-viral protein is characterized in that the anti-viral protein is fusion protein and comprises a transmembrane peptide structural domain and a tandem body which is formed through at least two cytosine deaminase structural domains originated from an APOBEC family, a transmembrane peptide structural domain and various cytosine deaminase structural domains. The transmembrane peptide structural domain in the anti-viral protein provided by the invention ensures the anti-viral protein to have the transmembrane capability and to freely shuttle among cells and enters the cells in a non-receptor and non-energy dependent way; the cytosine deaminase structural domains originated from the APOBEC family ensures that the anti-viral protein can effectively inhibit the reproduction of human immunodeficiency virus and/ or hepatitis B virus after entering cells; because the non-essential sequences in the APOBEC family protein molecules are removed, not only the antiviral activity of the APOBEC family protein molecules is preserved, but also the immunogenicity of the anti-viral protein is reduced, and the transmembrane efficiency of the anti-viral protein is enhanced.

The invention discloses an antiviral protein RC28, the amino acid thereof is shown in SEQ ID NO.1, and the preparation method thereof comprises the following steps: crude separation is carried out to obtain crude extract of RC28, molecular sieve chromatography and ion exchange chromatography are used to further carry out separation and purification to obtain RC28 protein product. The antiviral protein RC28 of the invention has good antiviral activity, and provides an efficient and safe new way for treating virus infection, in particular to enveloped virus infection diseases.

The invention relates to the transgenic technology of bombyx mori, in particular to the application of enhancer Hr3 for promoting Hycu-EP32 protein increment expression. The increment expression vector takes a transposition vector pBac [3 * P3 - EGFPafm] as the base vector; and the transposition vector is sequentially connected with enhancer Hr3, a 39kP promotor, a Hycu-EP32 gene and a termination signal sequence. In the invention, transgenic increment expression exogenous antiviral protein is used for preparing anti-BmNPV bombyx mori, which is the first method of improving the resistance of bombyx mori by adopting transgenic increment expression exogenous resistant protein in diapause bombyx mori; the Hycu-EP32 protein can be expressed in each growth period, so as to overcome the defect that the normal bombyx mori cannot express Hycu-EP32, and provide convenience for inhibiting viral breeding by utilizing Hycu-EP32 protein in each period; and the expressed increment of protein increases with viral increment, so as to reduce impact of expression exogenous protein on normal physiological activities and economic characters of bombyx mori, and obviously improve the resistance of bombyx mori.

The invention discloses application of IFITM3 (interferon induced transmembrane protein 3) packaging exosome to preparation of a dengue virus infection prevention medicine. A preparation method of the exosome comprises the following steps: collecting the supernatant of an HUVEC (Human Umbilical Vein Endothelial Cell) culture medium with high-expressed IFITM3, and performing sucrose density gradient ultracentrifugation on the supernatant to prepare the exosome. The action mechanism is that the exosome with high-expressed IFITM3 can strongly inhibit dengue virus from adsorbing and penetrating host cells. The invention builds a new strategy for resisting dengue virus with the IFITM3 packaging exosome. Whether the antiviral protein packaging exosome can replace interferon to be directly applied to research and development of antiviral medicines opens up a new vision and new application of humanized antiviral protein in the field of antiviral prevention and treatment, thus providing new ideas and directions for development of novel antiviral medicines.

The invention discloses a microparticle chemiluminescence detection kit for immunoassay of antiviral protein MxA, which comprises a coating reaction buffer, a magnetic microparticle solution, a secondantiviral protein MxA monoclonal antibody solution, a first luminescent liquid, a second luminescent liquid, a whole blood lysing solution, different concentrations of antiviral protein MxA antigen standard solution and concentrated washing solution. The invention fills the gap in the production of microparticle chemiluminescence detection reagent for immunoassay of antiviral protein MxA in China, which has the advantages of simple operation, high sensitivity, wide linear range, stable results, good safety, easy automation, and has broad application prospects in clinical testing.

The invention discloses application of an interferon kappa (IFN-kappa) in preparation of anti-enveloped virus medicines, belonging to the field of anti-virus medicines. A nucleotide sequence of a coding gene of the IFN-kappa is as shown in SEQ ID NO:1, and an amino acid sequence is as shown in SEQ ID NO:2; and an enveloped virus comprises but is not limited to flu and ZIKV. The condition that expression of antiviral protein IFITM3 is induced by IFN-kappa is found, so that infection and replication of flu virus and the ZIKV are prohibited. IFN-kappa can effectively prohibit infection and replication of the enveloped-virus in an in-vitro cell model, so as to relieve various diseases caused by massive replication of the flu virus and the ZIKV. The above finding shows that the IFN-kappa can be used for preparing the anti-enveloped virus medicines as well as medicines for treating and/or preventing various diseases caused by the enveloped-virus.

The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.

The invention discloses a recombinant antiviral protein, nucleic acid coding the recombinant antiviral protein, a recombinant expression vector comprising the nucleic acid, a transformant comprising the recombinant expression vector, a method for preparing the recombinant antiviral protein and an application of the recombinant antiviral protein to preparation of medicines resistant to porcine reproductive and respiratory syndrome viruses (PRRSV). The recombinant antiviral protein comprises a P9 peptide at a terminal N and an ISG20 protein at a terminal C, wherein the P9 peptide and the ISG20 protein are covalently fused; an amino acid sequence of the P9 peptide is shown in SEQ ID NO.1. The recombinant antiviral protein can effectively inhibit synthesis of ribonucleic acid (RNA) of the PRRSV and block replication of the PRRSV, has very high antiviral ability and high target specificity and also has very low toxicity toward cells.

The invention discloses primers for obtaining genes of bovine interferon alpha and a preparation method for recombinant bovine interferon alpha. The preparation method comprises the following steps: a, obtaining genes of bovine interferon alpha; b, constructing a cloning vector; c, constructing an expression vector; d, expressing recombinant protein; e, preparing a recombinant bovine interferon alpha crude product; and f, purifying the bovine interferon alpha crude product. Compared with the prior art, the bovine interferon alpha is a cell factor capable of inducing bovine cells to generate various broad-spectrum antiviral proteins and can be used for treating diseases caused by bovine vesicular stomatitis virus, foot and mouth disease virus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and the like.

The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an antiviral protein, antiviral peptide, or antiviral conjugate comprising at least nine contiguous amino acids of SEQ ID NO: 2, wherein the at least nine contiguous amino acids are nonglycosylated and have antiviral activity, whereupon the influenza viral infection is inhibited.

The invention discloses a latex-enhanced immunoturbidimetric assay detection single reagent for antiviral protein MxA and a preparation method thereof. A single reagent is adopted, mixing is not needed, the sensitivity is high, the detection speed is high, various samples such as the whole blood, serum and plasma can be directly measured. Therefore, the reagent can be widely applied to various transmission or scattering analyzers including a common biochemical analyzer, a specific protein analyzer and the like.

Disclosed are recombinant plant cells, plant cell parts, plant parts and transgenic plants containing a DNA molecule comprising a sequence encoding a Pokeweed Antiviral Protein (PAP) II protein. PAP II proteins include full length, wild-type PAP II and substantially nontoxic mutants or analogs including fragments thereof truncated at the C-terminus and other PAP II proteins having an intact catalytic active site amino acid residue E172 but that also have at least one amino acid substitution or deletion, and possess anti-viral and/or anti-fungal activity. DNA molecules comprising sequences encoding the mutants or analogs, as well as the isolated and purified PAP II proteins per se, are also disclosed. Methods of identifying nontoxic PAP II mutants are further disclosed.

Transgenic plants that produce a PAP II protein exhibit anti-viral and/or anti-fungal activity. Virtually all flowering plants are included. Seed derived from the transgenic plants are also provided.

The invention belongs to the field of medicines, and relates to a method for extracting and purifying pokeweed antiviral protein from pokeweed. The method comprises the following steps: extracting total protein from pokeweed leaves, performing precipitation with ammonium sulfate salt to obtain pokeweed antiviral crude protein, dissolving the pokeweed antiviral crude protein in a Tris-HCl buffer solution, performing further purification by adopting anion exchange chromatography and cation exchange chromatography, performing elution to obtain pokeweed antiviral protein solution, and performing ultrafiltration concentration and vacuum freeze drying to obtain the pokeweed antiviral protein with the purity of more than or equal to 99%. The method performs salt precipitation crude purification,and performs a process path of further purification by adopting anion exchange chromatography and cation exchange chromatography so as to obtain the pokeweed antiviral protein with the purity of morethan or equal to 99%, so that the problems of low purity of the extracted pokeweed antiviral protein in the prior art and lack of a high-purity pokeweed antiviral protein reference substance and a standard substance are solved, and the pokeweed antiviral protein has good clinical application prospect.

Disclosed is a method for treating virosis, wherein viruses causing virosis can be killed by multiple antiviral proteins produced by interferon evoked cells generated by virus type vaccine stimulation organism, thus curing the virosis. Different dosage, administration mode and and time can be employed for the patients.

The invention provides a new anti-human papilloma virus (HPV) and endometritis preparation comprising the following components by weight: 0.0001-10 parts of plant antiviral protein-D, 0.0001-50 parts of anti-HPV IgY, 1-15 parts of composite plant enzyme and 1-80 parts of accessories, the new preparation has the anti-human papilloma virus (HPV) and endometritis elimination effects, has the effects of resistance to infection of a variety of viral diseases and bacterial infection, and has no toxic and side effect.

The invention concerns a Ribosome inactibating protein (RIPS) Chinese mainland protein separated from plants which plays a role in anti-AIDS through catalyzing rRNA depurination of prokaryotic and eukaryotic ribosome with highly conserved stem-loop structure at the surface. The invention involves a Tat protein, the basic amino acid enrichment domain of which is protein transduction domain (PTD) and able to carry many exogenous protein directly into cells as protein orientation of cytokines or toxin. The invention involves a fusion protein of Tat and Chinese antiviral protein mutant. Performing deletion mutation to CAP using Quick-mutagenesis site-directed mutagenesis technology: 22 amino acid deletion in N-terminal, 29 amino acid deletion in C-terminal and site-specific mutagenesis: 151KI152/151AA152, 191FN192/191AA192. The recombinant protein of the invention has biological activity of anti-HIV-1 in vitro. It is found that CAP deletion and site-specific mutagenesis in fusion gene can significantly reduce its ability to combine with rRNA (cytotoxicity), however, without influence to its ability of combination of HIV RNA (anti-HIV activity), has more clinical application.

The invention relates to the technical field of freshwater fish genetic engineering, and discloses a separated carp antiviral protein Pdcd6ip and an antiviral activity. The nucleotide sequence of a carp antiviral protein Pdcd6ip gene is a sequence shown in 1st-2610th bp in SEQ ID NO:1, and an encoded amino acid sequence is a sequence shown in SEQ ID NO:2. Tests indicate that the expression of thecloned Pdcd6ip protein can affect the proliferation of spring viremia of carp virus (SVCV), the Pdcd6ip protein plays an important role in the process of cells resisting to SVCV infection, and at thesame time, the effect on the cell activity of ordinary cells is low. The gene or protein provides a new target for preparing anti-SVCV drugs.